Clear cell renal cell carcinoma (ccRCC) is the most common form of adult kidney cancer, characterized by the presence of inactivating mutations in the VHL gene in most cases 1, 2 , and by infrequent somatic mutations in known cancer genes. To determine further the genetics of ccRCC, we have sequenced 101 cases through 3,544 protein-coding genes. Here we report the identification of inactivating mutations in two genes encoding enzymes involved in histone modification-SETD2, a histone H3 lysine 36 methyltransferase, and JARID1C (also known as KDM5C), a histone H3 lysine 4 demethylase-as well as mutations in the histone H3 lysine 27 demethylase, UTX (KMD6A), that we recently reported 3 . The results highlight the role of mutations in components of the chromatin modification machinery in human cancer. Furthermore, NF2 mutations were found in non-VHL mutated ccRCC, and several other probable cancer genes were identified. These results indicate that substantial genetic heterogeneity exists in a cancer type dominated by mutations in a single gene, and that systematic screens will be key to fully determining the somatic genetic architecture of cancer.
Renal cell carcinoma accounts for about 209,000 new cases per year worldwide and 102,000 deaths 2 . Compared to other adult carcinomas, the genetics of ccRCC are distinctive. Most ccRCCs have either somatic or germline inactivating mutations in the VHL gene, which are largely absent in other cancers. Known cancer genes that are frequently mutated in other adult epithelial cancers, for example the RAS genes, BRAF, TP53, RB (also known as RB1), CDKN2A, PIK3CA, PTEN, EGFR and ERBB2, make only a small contribution to ccRCC (http://www.sanger.ac.uk/genetics/CGP/cosmic/). To further determine the somatic genetics of ccRCC, we sequenced the coding exons of 3,544 genes in 101 ccRCCs ( Supplementary Table 1 for sample information), equating to approximately 745 megabases (Mb) of cancer genome sequenced. A full list of genes is given in Supplementary Table 2 and available online (http://www.sanger.ac.uk/genetics/CGP/Studies/). Copy number analyses using high-density single nucleotide polymorphism (SNP) array and genome-wide expression array analyses were also performed. The initial study was comprised of 96 primary pre-treatment tumours ( Table 1 ) and five ccRCC cell lines for which there was a matching lymphoblastoid line. All somatic mutations were confirmed by sequencing of the relevant exons in normal DNAs from the same individuals.
Five-hundred-and-fifteen somatic base substitutions and small insertions/deletions were identified in the initial study (Supplementary Table 3 ). This included 56 (55%) cases with mutations in VHL, a prevalence in agreement with other reports 4 . Evaluation of gene expression revealed two distinct phenotypes ( Fig. 1a ). Seventy-five out of 91 (82%) ccRCCs assessed for expression had upregulation of genes associated with cellular hypoxia 5, 6 , with most (49 out of 75, 65%) carrying VHL-inactivating point mutations. Loss of 3p, in which VHL resides, was the most frequent (88 out of 101, 87%) copy number change seen on SNP array analyses ( Supplementary Fig. 2 ; http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghHome. cgi). We identified a significantly (P , 0.001; Supplementary Methods) higher proportion of small insertion/deletion mutations in ccRCC than in screens of the coding exons in pancreatic cancer 7 , glioma 8 or several cancer types screened through all protein kinase genes 9 . This may indicate an unidentified DNA-repair defect, a previously uncharacterized exposure, or a combination of the two. The average mutation prevalence was 0.75 Mb-lower than that observed for other Grading was according to ref. 26 , with increasing grade reflecting higher levels of nuclear atypia. TNM staging was according to the American Joint Committee on Cancer 27 , and is based on the extent of the tumour (T), the extent of spread to the lymph nodes (N), and the presence of metastasis (M). Stage I disease is localized to the kidney through to stage IV disease with distant metastasis. NA, not available.
adult cancers 9 . The mutation spectrum in ccRCC was unremarkable, being dominated by C to T/G to A transitions ( Supplementary Fig. 1 ), as has been noted in several other adult cancers 9 . Genes with two or more non-synonymous mutations, a subset of those with at least one truncating mutation and/or identified as being of particular interest ( Supplementary Table 5 ), were sequenced in a follow-up series of 311 primary RCC samples comprising 246 ccRCCs plus 65 other samples of non-clear-cell histology. Combined initial and follow-up screening data (Supplementary Tables 3 and 6 ) minus VHL mutations were subjected to statistical analyses for the presence of positive selection, that is, clustering of somatic mutations in a subset of genes consistent with a role in cancer development (Supplementary Methods). Five genes (SETD2, JARID1C, NF2, UTX and MLL2) have statistical support for being under selection at a false-discovery rate (FDR) , 0.2, with all but MLL2 having strong evidence for selection by truncating mutations (Supplementary Table 7 ).
Twelve out of 407 (3%) ccRCC cases had somatic truncating mutations in SETD2, which encodes a histone H3K36 methyltransferase 10 , and 13 out of 407 (3%) had truncating mutations in JARID1C, which encodes a histone H3K4 demethylase 11 (Table 2 and Supplementary  Table 8 ). Screening of 779 cancer cell lines identified an extra SETD2 homozygous truncating mutation in the A498 ccRCC line. Because assessment of homozygous deletions in primary tumour material is challenging, it is possible that we have underestimated the prevalence of inactivating mutations in these genes. No mutations were found in SETD2 or JARID1C in the subset of non-clear-cell cancers included in the follow-up screen, and there was little evidence for involvement in other tumour types in cancer cell lines ( Supplementary Table 9 ) in contrast to UTX 3 . Eighty-eight per cent (21 out of 24) of samples with truncating SETD2 and JARID1C mutations had VHL mutations and/or the hypoxia expression phenotype (Fig. 1a, b ). One ccRCC cell line, LB996-RCC, in addition to containing a NF2-truncating mutation, was found to harbour both a truncating UTX and SETD2 mutation, suggesting that these are not redundant in ccRCC development.
Comparisons of the expression phenotypes of SETD2-and JARID1C-mutated ccRCCs showed a signature for both, and also marked difference between the two ( Fig. 2a and Supplementary Table  10a , b). Large-scale transcriptional deregulation was noted in the SETD2-mutated subset, with 298 genes showing significant differences in expression relative to other cancers analysed (FDR , 0.05, P 5 0.001 for association with SETD2 mutation; Fig. 2b and Supplementary Table  10a ). Nearly all of the significant expression changes were twofold or less. In contrast, JARID1C mutant cancers showed a much more restricted signature ( Fig. 2c and Supplementary Table 10b ). Eighteen genes showed significant expression changes in cancers with JARID1C mutations (FDR , 0.05), including the metallothionein genes. Of note, those ccRCCs with UTX mutations were also found to overexpress metallothioneins (Fig. 2c, d and Supplementary Table 10c ), suggesting overlap in transcriptional deregulation caused by JARID1C and UTX loss ( Fig. 2e ). Indeed, UTX and JARID1C are both implicated in H3K4 methylation status-JARID1C directly as a H3K4 demethylase 11 , and UTX as a component of the MLL2/3 H3K4 methylation complex 12, 13 . In support of the importance of this axis, MLL2, an H3K4 methylase, was one of the other genes identified as a probable ccRCC cancer gene in our statistical analyses.
Five somatic truncating mutations in the NF2 gene were found in the full screen ( Table 2 and Supplementary Table 8 ). Germline NF2-truncating mutations predispose to neurofibromatosis II, characterized by predisposition to acoustic neuromas, meningiomas and schwannomas 14 . Somatic truncating mutations have been EGLN3 is the most upregulated gene in the hypoxic group. JARID1C (orange bar) and SETD2 (green bar) mutant tumours are all clustered in the hypoxic group, whereas the NF2 mutant tumour (purple bar) is in the non-hypoxic group. b, A similar pattern is observed in RCC cell lines, with EGLN3 again being the most upregulated gene in the hypoxic group. Five NF2 mutant cell lines cluster in the non-hypoxic group. c, Clustering of NF2 mutant samples within the low VEGF expression/non-hypoxic subgroup of ccRCC. In contrast to JARID1C and SETD2, none of the NF2-mutant ccRCC samples harboured a VHL mutation or exhibited the hypoxia expression phenotype (Fig. 1a, b) . These data indicate that somatic NF2 mutations may account for a proportion of this subset of cases. The screen identified a number of other potential new cancer genes in ccRCC (Table 2 and Supplementary Table 8 ), including the identification of three samples with somatic HIF1A-truncating mutations. Only these truncating mutations were found, and two of the three samples had VHL point mutations. It has been shown that HIF1a and HIF2a have overlapping but non-identical targets and activities. HIF1a antagonises MYC function, whereas HIF2a cooperates with MYC 15, 16 . In VHL disease-associated ccRCC, frequent absence of HIF1a staining with a preponderance of HIF2a positivity has been reported 17 , suggesting that there may be selection for loss of HIF1a during ccRCC progression. Three different truncating mutations (Table 2 and Supplementary Table 8 ) were also identified in the DNA mismatch-repair gene PMS1. Notably, two truncating mutations found in the follow-up screen proved to be germline alleles. To our knowledge, this is the first report of PMS1 mutations in ccRCC. Both germline cases were late onset (70 and 71 years old) without documented family history, and none of the three mutated cancers were microsatellite-unstable (data not shown). No truncating variants were detected by sequencing all coding exons of PMS1 in 528 normal controls, indicating the germline alleles are not polymorphisms. Determining the extent to which truncating germline PMS1 alleles contribute to ccRCC will require larger cohort studies.
Somatic truncating mutations were detected in both initial and follow-up screens in WRN, NBN and ZUBR1 (also known as UBR4) genes ( Table 2 and Supplementary Table 8 ). WRN and NBN are involved in DNA double-strand break repair 18 , and recessive mutations in WRN and NBN give rise to Werner syndrome and Nijmegen breakage syndrome, respectively, both of which predispose to cancer 19, 20 . ZUBR1 encodes the p600 retinoblastoma-associated protein, and has been shown to be a cellular target for the bovine papilloma virus 21 and human papilloma type 16 E7 proteins 22 . The interaction of E7 with p600 mediates cellular transformation independently of RB1 binding 21, 22 , and the knockdown of p600 in the absence of E7 induces anchorageindependent growth 22 .
VHL inactivation alone induces senescence, suggesting a requirement for further mutations to further drive ccRCC development in VHL mutant cases 23 . Conditional knockout of the VHL gene in renal epithelium does not generate any RCC phenotype, consistent with a need for additional hits (B.T.T., unpublished results). The mutations in the genes reported here probably contribute in this regard, and the work further suggests that there are likely to be other mutated genes in ccRCC. As exemplified here, even in the context of a very prevalent driver mutation and dominant histological subtype, the numbers of cancers needed to adequately explore and capture the somatic genetic heterogeneity may be quite large, strongly supporting current efforts to expand mutational screening to large sample series with ultimately full genome sequencing of hundreds of cancers of all major subtypes (http://www.icgc.org/). For ccRCC, the data presented here will provide insights into its pathogenesis and the opportunity to understand the role of genetic subtypes in clinical behaviour and response to treatment.
METHODS SUMMARY
Genomic DNA samples were obtained from clinical tumour samples (.80% tumour cellularity), matching peripheral blood/adjacent normal kidney taken at nephrectomy and cancer cell lines as indicated using standard protocols. Collection and use of patient samples were approved by the appropriate Institutional Review Board (IRB) of each Institution, in addition to this study having Local Research Ethics Committee (LREC) approval locally. RCC clinical samples and cell lines screened are given in Supplementary Table 1 . SNPArray hybridization on the SNP6.0 platform was as per Affymetrix Protocols and as described at http://www.sanger.ac.uk/cgi-bin/genetics/CGP/cghviewer/CghHome. cgi. PCR-based exon resequencing was performed and data analysed as previously described 9 , with sequencing traces being first analysed using a semi-automated system 24 followed by manual inspection. PCR primer sequences are available for download at http://www.sanger.ac.uk/genetics/CGP/Studies/Renal/. Overall significance of an excess of non-silent mutations was determined using the methods previously described 25 , and is described in detail in the Supplementary Methods. RNA was extracted from fresh frozen patient tissue with Trizol according to manufacturer's instructions (Invitrogen) and analysed using human U133 Plus 2.0 Array probe sets according to manufacturer's instructions (Affymetrix). Summarized expression values were computed using the robust multichip average (RMA) approach, corrected for batch effects, and used for clustering analysis and discriminate gene analysis using a moderated t-statistic. Further detail on analysis can be found in the Supplementary Methods. a, Genes (n 5 298) that are deregulated in tumour samples containing nonsynonymous SETD2 mutations (n 5 13) versus samples lacking such mutations (n 5 77) are plotted as a heatmap. Red indicates increased gene expression compared to the average expression in the tumour samples, blue indicates decreased gene expression. b, The most significantly deregulated genes in the SETD2 mutant samples. c, Heatmap of genes (n 5 18) that are deregulated in tumour samples that contain non-synonymous JARD1C mutations (n 5 10) versus samples lacking such mutations (n 5 80). The asterisks highlight the sample containing the S1222P mutation. d, Expression of the MT1G gene in the tumour samples. Expression values are shown relative to non-diseased tissue and log 2 -transformed such that a log 2transformed value of 22 is equivalent to a fourfold decrease in expression relative to non-diseased kidney. e, Metallothionein genes (n 5 8) were examined for deregulated expression in JARID1C and UTX mutant samples. Significantly deregulated genes are indicated.
